A pharmaceutical formulation comprising a long-acting human growth hormone (hGH) for use in a method of treating growth hormone deficiency in children, wherein the long-acting growth hormone formulation is administered to a patient in a bracketed dosage regimen, in which a range of patients' weights is allocated a constant dose of mg hGH equivalents per week, which weight range is referred to as a weight bracket, wherein dosage increases occur in a step-wise manner and wherein a bracketed dosage regimen has between 3 and 15 weight brackets, wherein the dose a patient receives measured in mg hGH equivalents is the same for all patients within that weight bracket, and wherein the dose of one weight falling into a particular weight bracket corresponds to the dose given in a respective fixed dosage regimen, which is a dose ranging from and including 0.14 to 0.40 mg/kg/week, and wherein patients of the same bracket having a lower weight receive a dose that is higher than said dose of the fixed dosage regimen and patients of the same bracket having a higher weight receive a dose that is lower than said dose of the fixed dosage regimen, wherein if a patient's weight exceeds the weight of a particular weight bracket the dose is increased to the dose of the next weight bracket, which dose of growth hormone equivalents in two neighboring brackets increases by at least 10%, and wherein the long-acting growth hormone is ACP-001 or ACP-011 having the structure of formula wherein D is a hGH moiety connected to the rest of the molecule through an amine functional group; and p1, p2, p3, p4 range from 200 to 250 for ACP-011 and from 400 to 500 for ACP-001. wherein the long-acting growth hormone formulation is administered to a patient in a bracketed dosage regimen, in which a range of patients' weights is allocated a constant dose of mg hGH equivalents per week, which weight range is referred to as a weight bracket, wherein dosage increases occur in a step-wise manner and wherein a bracketed dosage regimen has between 3 and 15 weight brackets, wherein the dose a patient receives measured in mg hGH equivalents is the same for all patients within that weight bracket, and wherein the dose of one weight falling into a particular weight bracket corresponds to the dose given in a respective fixed dosage regimen, which is a dose ranging from and including 0.14 to 0.40 mg/kg/week, and wherein patients of the same bracket having a lower weight receive a dose that is higher than said dose of the fixed dosage regimen and patients of the same bracket having a higher weight receive a dose that is lower than said dose of the fixed dosage regimen, wherein if a patient's weight exceeds the weight of a particular weight bracket the dose is increased to the dose of the next weight bracket, which dose of growth hormone equivalents in two neighboring brackets increases by at least 10%, and wherein the long-acting growth hormone is ACP-001 or ACP-011 having the structure of formula wherein D is a hGH moiety connected to the rest of the molecule through an amine functional group; and p1, p2, p3, p4 range from 200 to 250 for ACP-011 and from 400 to 500 for ACP-001. D is a hGH moiety connected to the rest of the molecule through an amine functional group; and p1, p2, p3, p4 range from 200 to 250 for ACP-011 and from 400 to 500 for ACP-001.